INTRODUCTION: Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy. METHODS: A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC. RESULTS: The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes. CONCLUSION: miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.
INTRODUCTION: Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy. METHODS: A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC. RESULTS: The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes. CONCLUSION: miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.
Authors: T Kuroshima; M Aoyagi; M Yasuda; T Kitamura; J P Jehung; M Ishikawa; Y Kitagawa; Y Totsuka; M Shindoh; F Higashino Journal: Oncogene Date: 2011-02-14 Impact factor: 9.867
Authors: Luke A Selth; Scott Townley; Joanna L Gillis; Aleksandra M Ochnik; Krisna Murti; Robyn J Macfarlane; Kim N Chi; Villis R Marshall; Wayne D Tilley; Lisa M Butler Journal: Int J Cancer Date: 2011-11-03 Impact factor: 7.396
Authors: Kim M Smits; Trupti Paranjape; Sunitha Nallur; Kim A D Wouters; Matty P Weijenberg; Leo J Schouten; Piet A van den Brandt; Fred T Bosman; Joanne B Weidhaas; Manon van Engeland Journal: Clin Cancer Res Date: 2011-10-12 Impact factor: 12.531
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: Heather H Cheng; Melissa Plets; Hongli Li; Celestia S Higano; Catherine M Tangen; Neeraj Agarwal; Nicholas J Vogelzang; Maha Hussain; Ian M Thompson; Muneesh Tewari; Evan Y Yu Journal: Prostate Date: 2017-11-06 Impact factor: 4.104
Authors: Hui-Ming Lin; Kate L Mahon; Calan Spielman; Howard Gurney; Girish Mallesara; Martin R Stockler; Patricia Bastick; Karen Briscoe; Gavin Marx; Alexander Swarbrick; Lisa G Horvath Journal: Br J Cancer Date: 2017-03-09 Impact factor: 7.640
Authors: Michael R Epis; Keith M Giles; Dianne J Beveridge; Kirsty L Richardson; Patrick A Candy; Lisa M Stuart; Jacqueline Bentel; Ronald J Cohen; Peter J Leedman Journal: Oncotarget Date: 2017-06-27